Table 3.
Clinical outcomes of patients who received pentoxifylline and tocopherol therapy for management of MRONJ.
| Age (Years) | Cause of Anti-Resorptive Treatment | Gender | Type of MRONJ-Related Drug | UCONNS Score | Stage of MRONJ | Site of MRONJ | Outcomes |
|---|---|---|---|---|---|---|---|
| 68 | Cancer | Female | Alendronate | 12 | Stage II | Mandible | Healed |
| 65 | Cancer | Female | Zoledronate | 23 | Stage II | Mandible | Worsened |
| 53 | Cancer | Female | Zoledronate | 31 | Stage II | Mandible | Stable |
| 51 | Cancer | Female | Zoledronate-Denosumab | 24 | Stage II | Maxilla | Worsened |
| 93 | Osteoporosis | Female | Alendronate-Denosumab | 13 | Stage II | Maxilla/Mandible | Healed |
| 85 | Cancer | Female | Zoledronate | 26 | Stage II | Maxilla | Healed |
| 65 | Cancer | Male | Denosumab | 22 | Stage II | Mandible | Healed |
| 90 | Osteoporosis | Female | Alendronate | 8 | Stage II | Maxilla | Healed |
| 77 | Cancer | Male | Zoledronate | 21 | Stage II | Mandible | Healed |